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The aim of this study was to explore perceptions of patient-centered care (PCC) among Veterans with gastroesophageal 
reflux disease (GERD) on proton pump inhibitor (PPI) therapy using patient-reported outcome (PRO) measures. We 
used three validated surveys to measure PCC concepts in a national sample of Veterans with GERD on PPI therapy. 
The Combined Outcome Measure for Risk Communication and Treatment Decision Making Effectiveness 
(COMRADE) measures patient experiences with risk communication and decision-making. The Patient Activation 
Measure (PAM) evaluates confidence and knowledge needed for self-management. The Patient Assessment of Care for 
Chronic Conditions (PACIC) assesses views of chronic care received. We used descriptive statistics to describe patient 
characteristics and PCC outcomes. Respondents (n=444) were mostly male (95.1%) with a mean age of 67.7 years. The 
mean COMRADE score measuring patient experiences with risk communication was 55.3 (SD=19.0). The mean PAM 
score was 56.1 (SD=19.2); 47.8% of respondents were considered disengaged patients lacking confidence and knowledge 
for self-management. The mean PACIC summary score was 3.03 (SD=1.2), with highest scores in the Delivery System 
Design/Decision Support (3.38, SD=1.2) subscale, and lowest scores in the Follow-up/Coordination subscale (2.58, 
SD=1.3). Veterans with GERD reported that care was well-organized and supportive in enhancing decision-making. 
Potential gaps in patient experiences may exist in delivering follow-up care, enhancing patient activation, and informing 
patients about risks of available GERD treatments. This is the first study to evaluate patient perceptions of PCC in a 
national sample of Veterans with GERD on PPI therapy. Findings can inform further investigation and development of 
targeted interventions to enhance the experience of PCC for individuals with GERD. 
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Gastroesophageal reflux disease (GERD) is a common 
chronic condition that affects up to 28% of the North 
American population.1 Among all digestive diseases in the 
United States, GERD accounts for the highest direct 
health care costs and represents the leading diagnosis in 
the outpatient care setting.2-3 The disease is characterized 
by a broad range of troublesome esophageal symptoms, 
including heartburn, acid regurgitation, reflux esophagitis, 
stricture, Barrett’s esophagus, and adenocarcinoma, as well 
as several extraesophageal complications.4-5 In light of the 
complex nature and increasing prevalence, there is 
considerable variability around the impact of GERD 
symptoms on patients.6-8  
 
This variability extends into the delivery of chronic care 
for individuals with GERD, where substantial differences 
and gaps exist in establishing initial diagnoses, 
coordinating follow-up care, and measuring quality of 
care.9-11 Furthermore, a central challenge in caring for 
individuals with GERD stems from treatment 
management with proton pump inhibitor (PPI) therapy. 
Although widely regarded as an effective treatment 
strategy, numerous studies have highlighted trends of 
inappropriate use and suboptimal dosing of PPI therapy.12-
15 These patterns are problematic given the rising costs and 
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documented health risks associated with long-term PPI 
use,16-19 and given evidence that a significant proportion of 
PPI users continues to experience breakthrough GERD 
symptoms and reports lower levels of satisfaction with 
treatment.9, 20  
 
To enhance care for patients with GERD, a patient-centric 
model may be especially beneficial. Patient-centered care 
(PCC) calls for the redesign of health services to tailor care 
around patient needs and preferences, enhance quality of 
care, and integrate care processes.21 The model may be 
well-suited for GERD care because of its individualized 
approach to address complex, chronic diseases,22-23 its 
emphasis on efficient and evidence-based care, and its 
focus on patient engagement.24 In light of increased media 
coverage around the risks of PPI treatment and 
subsequently heightened patient concerns,25 patient-
centered approaches that are responsive to individual 
needs and preferences may be particularly helpful. 
 
PCC is tied closely to patients’ experience of care. 
Cornerstones of PCC—including understanding the 
patient journey and providing personalized care—are 
aligned with current definitions of the patient experience.26 
These are increasingly important to consider given the 
inclusion of patient experience as an indicator of quality 
and performance within health care organizations.27 To 
our knowledge, no published studies have focused on 
patient experiences related to GERD, but these are needed 
to understand and improve care around patients’ unique 
needs. Measuring patient experiences can be challenging; 
however, prior literature suggests that successful 
approaches are centered on what matters most to 
patients.28 Thus, PCC outcomes that focus on patient 
views of their own care may offer a useful lens to study 
patient experiences.  
 
In the United States, the Veterans Affairs (VA) Health 
Care System is one of many health care organizations to 
adopt PCC.29 An essential component of PCC 
implementation is obtaining patient-level evaluations of 
care to better understand patient experiences and 
outcomes.30 Deriving patient-reported insights, moreover, 
is an important prerequisite for developing strategies that 
enhance care in a way that aligns with the needs of patients 
with GERD.31 Although patient-reported outcome (PRO) 
measures have been used to assess clinical symptoms 
among patients with GERD,32 few studies demonstrate the 
use of PRO measures to describe PCC outcomes, 
including experiences and perspectives around chronic 
care delivery and organization, patient activation, decision-
making, and self-management. In particular, limited data 
exist that describe PCC outcomes among Veteran patients 
with GERD on PPI therapy, yet this information is 
needed to enhance the quality of PCC for an increasingly 
large and diverse population affected by GERD. Our aim 
was to explore perceptions of PCC among Veteran 




Study Design and Respondents 
The Center for Evaluation of Practices and Experiences of 
Patient Centered Care (CEPEP) is a VA funded project 
(PEC-13-002, PI: LaVela) to evaluate a range of PCC 
outcomes across the VA Health Care System. As part of 
this project, we conducted a cross-sectional mailed survey 
of Veterans with GERD who received care from eight 
nationally representative VA health care facilities across 
the northeastern/mid-Atlantic, southeastern, southwestern 
and western regions. During February and March 2013, we 
mailed a cover letter describing the purpose of the study, a 
survey, and a pre-paid VA business reply envelope to 
eligible respondents. We performed a follow-up mailing of 
the survey in mid-2013 to Veterans who had not 
responded to the original mailing. We used VA 
administrative databases to identify eligible respondents 
and used stratified random sampling and Dillman’s sample 
size selection equation33 to ensure adequate power and 
generalizability of our findings to the broader Veteran 
population. 
 
Inclusion criteria for this study were Veteran patients with 
a clinical outpatient diagnosis of GERD (ICD-9 codes: 
530.81 and 530.11) who were prescribed PPI therapy 
within 30 days following GERD diagnosis and who had 
received health care from a VA facility during the prior 6 
months. PPI doses (standard or high dose prescriptions) 
were calculated as the ratio of quantity of 
medication/day’s supply of medication at initial 
prescription. Long-term PPI use was defined as six 
months or more of therapy. We used VA administrative 
databases to extract GERD and other chronic condition 
data, as well as health care utilization information for a 
one-year period (October 1, 2012 – September 30, 2013) 
for all respondents. 
 
This study was conducted as part of a larger quality 
improvement effort by VA health care facilities to evaluate 
PCC using methods that capture patient perspectives. 
  
Survey Measures and Data Sources 
The survey included questions on patient demographics 
(age, sex, race, ethnicity, education), recent hospital or 
doctor visits, and three validated PRO instruments that 
assessed PCC outcome measures. These measures 
included the (1) Combined Outcome Measure for Risk 
Communication and Treatment Decision Making 
Effectiveness (COMRADE), the (2) Patient Activation 
Measure (PAM) instrument, and the (3) Patient 
Assessment of Care for Chronic Conditions (PACIC). 
Each measure is intended to capture key elements of the 
patient experience,28 including patient-provider 




Patient Experience Journal, Volume 5, Issue 3 – 2018 151 
communication, decision making, patient involvement in 
care, and coordination and continuity of care.  
 
COMRADE. The COMRADE is a 20-item scale that 
assesses levels of patient perception of effective risk 
communication and confidence in shared decision-making 
as it relates to medical treatment. The instrument subscales 
include risk communication and decision-making 
effectiveness and represent distinct shared decision-
making constructs.34 The risk communication subscale 
addresses the information exchange between patients and 
providers around the potential risks and benefits of 
treatment. The decision-making effectiveness subscale is 
focused on the outcome of the information exchange and 
decision-making processes.35 Items are evaluated on a 5-
point Likert scale (where 1=strongly disagree and 
5=strongly agree). Overall COMRADE scores are defined 
across a range of 0 to 100, where higher scores indicate 
better communication and outcomes, as well as more 
informed and effective decision-making.35  
 
PAM. The short-form version of the PAM is a 13-item 
instrument designed to measure the degree to which 
patients are engaged in their health care and possess the 
knowledge, skills and confidence needed for self-
management. The instrument helps generate a patient 
activation score that places respondents into one of four 
categories (levels 1-4), each representing an increasingly 
higher level of activation.36 Using a Likert scale, 
respondents are asked to evaluate their level of agreement 
with statements reflecting the 4-step developmental 
process of patient activation. Activation stages include 
Stage 1: believing the patient role is important; Stage 2: 
having the confidence, knowledge and skills needed to 
take action; Stage 3: taking action to maintain self-
management; Stage 4: sustaining the course under stress. 
PAM scores range from 1 to 100, where higher scores 
indicate better skills, knowledge and behaviors necessary 
for self-management as well as greater patient activation 
along the four stages. Raw scores are converted into an 
overall patient activation score and subsequently 
interpreted using a table developed by Hibbard and 
colleagues.36-37  
 
PACIC. The PACIC is a 20-item instrument that assesses 
patient perceptions of the chronic care received. The 
instrument is organized into five subscales that address 
elements of PCC as perceived by patients with chronic 
illness; these subscales include Patient Activation, Delivery 
System Design/Decision Support, Goal Setting, Problem 
Solving/Contextual Counseling, and Follow-
up/Coordination.38 Respondents are asked to evaluate 
chronic care received over the last six months. Individual 
PACIC items are scored on a 5-point Likert scale, where 
1=no/never and 5=yes/always. The overall PACIC 
summary score is the average of all 20 items. Subscales are 
scored by averaging the values of responses corresponding 
to each subscale. Higher scores indicate higher or more 




All analyses were conducted using SAS software version 
9.3 (SAS Institute Inc., Cary, NC). We used descriptive 
statistics to characterize the overall sample and assess PCC 
outcomes. We determined overall summary scores and 
subscale scores for each survey measure among Veterans 




The surveys were mailed to 1,777 Veteran patients with a 
GERD diagnosis who were prescribed PPIs. Of these, a 
total of 41 surveys were undeliverable, 11 patients had 
died, and 2 surveys were returned unopened or indicated 
as ‘not applicable,’ leaving 1,723 Veterans. The survey was 
completed by 444 Veteran patients (25.8% response rate) 
who had complete survey data for the COMRADE, PAM 
and PACIC instruments; these Veterans were included in 
the final analyses. 
 
The average age of our sample was 67.7 years (SD=11.3) 
and respondents were predominantly male (95.1%). A 
majority of respondents (70.4%) self-reported their 
race/ethnicity as non-Hispanic white.  Approximately 
23.3% reported completion of a college degree or higher 
level of education. Nearly 67.0% of respondents reported 
having three or more chronic conditions. Almost all 
respondents (99.8%) reported having one or more recent 
outpatient visits. Approximately 81.3% of respondents 
reported that they had seen a VA doctor or visited a VA 
health care facility in the six-month period preceding 
receipt of the survey (August 2012-February 2013). A 
majority of respondents (87.2%) reported long-term PPI 
use; and 53.1% had high total daily dose initial PPI 
prescriptions. Sample characteristics are presented in Table 
1. 
 
The mean COMRADE score measuring patient 
experiences with risk communication was 55.3 (SD=19.0); 
the mean score measuring patient experiences with 
decision-making was 61.0 (SD=17.3). Higher scores were 
generally achieved in the decision-making effectiveness 
subscale compared with the risk communication subscale. 
Within the decision-making subscale, highest scores 
(indicating more effective shared decision-making) were 
noted in items that asked about the extent to which 
respondents felt they could easily discuss their medical 
condition with their doctor (3.90, SD=1.24) and their level 
of confidence in treatment decisions that were made with 
their doctor (3.72, SD=1.27). Within the risk 
communication subscale, highest scores (denoting more 
effective information exchanges between patients and 
providers around treatment risks and benefits) were found  
Patient-centered care and gastroesophageal reflux disease, Balbale et. al 
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  Table 1. Sample characteristics 
 
Characteristic Mean (SD) or Percent 
Age (n = 438)   
mean (range, standard deviation) 67.74 (31 – 93, SD=11.33) 
Sex (n = 444)   
Male 95.05 
Female 4.95 







Hawaiian / Pacific Islander 0.46 
Ethnicity (n = 430)   
Hispanic 8.14 
Non-Hispanic 91.86 
Education (n = 442)   
Some or no college 76.70 
College Graduate 23.30 
Average distance from VA (miles) (n = 444)   
mean (range, standard deviation) 30.66 (0.12 – 314, SD=33.7) 
Recent doctor or hospital visits in last 6 months (n = 444)   
Yes, VA 81.31 
Yes, non-VA 24.10 
No 4.05 
Characteristic Mean (SD) or Percent 
Number of chronic conditions (n = 444)   
1-2  33.11 
3 or more  66.89 
Number of inpatient discharges  (n = 444)   
mean (range, standard deviation) 0.22 (0 – 5, SD=0.67) 
Length of stay a (n = 57)  
Mean (range, standard deviation)  9.14 (1 – 48, SD=10.59) 
Number of 24-hour observation stays (n = 444)  
mean (range, standard deviation) 0.04 (0 – 4, SD=0.29) 
Emergency room visits (n = 444)  
mean (range, standard deviation) 0.60 (0 – 12, SD=1.51) 
Outpatient visits  (n = 444)  
mean (range, standard deviation) 24.0 (0 – 234, SD=22.27) 
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specifically in items that addressed the extent to which 
patients felt they knew the advantages (3.84, SD=1.19) and 
disadvantages (3.88, SD=1.17) associated with treatment. 
Lowest scores were within the risk communication 
subscale. These items asked respondents to comment on 
the degree to which they felt their doctor had given them a 
chance to decide which treatment was best for themselves 
(3.35, SD=1.39), and the degree to which they felt their 
doctor had given them enough information about the 
various treatment options available (3.43, SD=1.36). Item 
responses for the COMRADE are presented in Table 2. 
 
The mean overall PAM score was 56.1 (SD=19.2). 
Approximately 47.8% of respondents were in the first and 
second stages of activation, indicating disengaged patients 
lacking confidence and knowledge to manage their health. 
Specifically, 28.4% were categorized in the first stage, and 
19.4% in the second. We found that 52.3% of respondents 
were in the third and fourth stages of activation, 
representing activated, goal-oriented patients who maintain 
self-management, and effectively engage with health care 
teams. Approximately 27.8% of respondents were 
classified in the third stage of patient activation, and 24.8% 
in the fourth stage. Highest scores were achieved in items 
that asked respondents about the extent to which they felt 
 





1.  The doctor made me aware of the different treatments available 3.45 (1.0 – 5.0) 1.31 
2.  The doctor gave me the chance to express my opinions about the different treatments 
available 
3.44 (1.0 – 5.0)1.34 
3.  The doctor gave me the chance to ask for as much information as I needed about the 
different treatment choices available  
3.46 (1.0 – 5.0) 1.38 
4.  The doctor gave me enough information about the treatment choices available  3.43 (1.0 – 5.0) 1.36 
5.  The doctor gave enough explanation of the information about the treatment choices  3.44 (1.0 – 5.0) 1.33 
6.  The information given to me was easy to understand 3.58 (1.0 – 5.0) 1.27 
7.  I know the advantages of treatment or not having treatment  3.84 (1.0 – 5.0) 1.19 
8.  I know the disadvantages of treatment or not having treatment  3.88 (1.0 – 5.0) 1.17 
9.  The doctor gave me a chance to decide which treatment I thought was best for me  3.35 (1.0 – 5.0) 1.39 
10.  The doctor gave me a chance to be involved in the decisions during the consultation  3.47 (1.0 – 5.0) 1.40 
11.  Overall, I am satisfied with the information I was given 3.61 (1.0 – 5.0) 1.27 
12.  My doctor and I agreed about which treatment (or no treatment) was best for me 3.62 (1.0 – 5.0) 1.33 
13.  I can easily discuss my condition again with my doctor 3.90 (1.0 – 5.0) 1.24 
14.  I am satisfied with the way in which the decision was made in the consultation 3.71 (1.0 – 5.0) 1.29 
15.  I am sure that the decision made was the right one for me personally 3.71 (1.0 – 5.0) 1.27 
16.  I am satisfied that I am adequately informed about the issues important to the decision 3.70 (1.0 – 5.0) 1.24 
17.  It’s clear which choice is best for me 3.64 (1.0 – 5.0) 1.28 
18.  I’m aware of the treatment choices I have 3.63 (1.0 – 5.0) 1.29 
19.  I feel an informed choice has been made 3.66 (1.0 – 5.0) 1.27 
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that they are the person who is responsible for managing 
their own health condition (3.34, SD=0.64), and the extent 
to which they believed that taking an active role in their 
own health care was the most important factor in 
determining their health and ability to function (3.42, 
SD=0.56). Lowest scores were noted in items that focused 
on respondents’ confidence in determining solutions when 
new problems occur with their health (2.60, SD=0.67), and 
their confidence in maintaining lifestyle changes, including 
diet and exercise, during times of stress (2.78, SD=0.69).  
Item responses for the PAM are shown in Table 3.    
  
The mean PACIC summary score was 3.03 (SD=1.2). 
Respondents achieved highest scores in the Delivery 
System Design/Decision Support (3.38, SD=1.2) and 
Patient Activation subscales (3.26, SD=1.3). Within these 
subscales, items with the highest scores included those that 
asked respondents about the extent to which they were 
encouraged to talk about any problems with their 
medicines or their effects (3.45, SD=1.36); the extent to 
which they were satisfied that their chronic care was well-
organized (3.72, SD=1.19); and the extent to which 
respondents were shown how steps they took to take care 
of their health influenced their chronic condition (3.32, 
SD=1.34). Lowest scores were in the Follow-
up/Coordination (2.58, SD=1.3) and Goal 
Setting/Tailoring subscales (2.98, SD=1.3). Within these 
subscales, lowest scores were specifically noted in items 
 
 





1.  When all is said and done, I am the person who is responsible for taking care of my 
health (n=443) 
3.34 (1.0 – 5.0) 0.64 
2.  Taking an active role in my own health care is the most important thing that affects 
my health (n=440) 
3.42 (1.0 – 5.0) 0.56 
3.  I am confident I can help prevent or reduce problems associated with my health 
(n=439) 
3.13 (1.0 – 5.0) 0.63 
4.  I know what each of my prescribed medications do (n=441) 3.10 (1.0 – 5.0) 0.66 
5.  I am confident that I can tell whether I need to go to the doctor or whether I can 
take care of a health problem myself (n=441) 
3.06 (1.0 – 5.0) 0.66 
6.  I am confident that I can tell a doctor concerns I have even when he or she does not 
ask (n=440) 
3.18 (1.0 – 5.0) 0.65 
7.  I am confident that I can follow through on medical treatments I may need to do at 
home (n=441) 
3.25 (1.0 – 5.0) 0.59 
8.  I understand my health problems and what causes them (n=439)  3.01 (1.0 – 5.0) 0.69 
9.  I know what treatments are available for my health problems (n=441) 2.87 (1.0 – 5.0) 0.70 
10.  I have been able to maintain (keep up with) lifestyle changes, like eating right or 
exercising (n=443) 
2.87 (1.0 – 5.0) 0.71 
11.  I know how to prevent problems with my health (n=433) 2.92 (1.0 – 5.0) 0.62 
12.  I am confident I can figure out solutions when new problems arise with my health 
(n=438) 
2.60 (1.0 – 5.0) 0.67 
13.  I am confident that I can maintain lifestyle changes, like eating right and exercising, 
even during times of stress (n=443) 
2.78 (1.0 – 5.0) 0.69 
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that addressed the extent to which respondents were asked 
how their visits with other doctors were going (2.60, 
SD=1.53); the extent to which respondents were 
encouraged to attend programs in their community that 
could help them (2.24, SD=1.44); and the extent to which 
respondents were encouraged to go to specific groups or 
classes to help them better cope with their chronic 
condition (2.78, SD=1.54).  Item responses for the PACIC 




To our knowledge, this is the first study to evaluate patient 
perceptions of PCC in a national sample of Veterans with 
GERD on PPI therapy. Using three validated PRO 
measures to assess PCC, we learned that perceptions of 
care among patients with GERD on PPI therapies were 
generally high and favorable overall. Patients reported that 
care was well-organized, supportive in enhancing their 
decision-making, and effective in improving their 
understanding of care. However, our findings also reveal 
several potential areas of improvement that can be 
 






1.  Asked for my ideas when we made a treatment plan (n=434) 3.11 (1.0 - 5.0) 1.37 
2.  Given choices about treatment to think about (n=428) 3.24 (1.0 – 5.0) 1.37 
3.  Asked to talk about any problems with my medicines or their effects (n=431) 3.45 (1.0 – 5.0) 1.36 
4.  Given a written list of things I should do to improve my health (n=438) 3.09 (1.0 – 5.0) 1.43 
5.  Satisfied that my care was well organized (n=434) 3.72 (1.0 – 5.0) 1.19 
6.  Shown how what I did to take care of myself influenced my condition (n=434) 3.36 (1.0 – 5.0) 1.34 
7.  Asked to talk about my goals in caring for my condition (n=434) 2.95 (1.0 – 5.0) 1.43 
8.  Helped to set specific goals to improve my eating or exercise (n=434)  3.02 (1.0 – 5.0) 1.43 
9.  Given a copy of my treatment plan (n=432) 3.02 (1.0 – 5.0) 1.52 
10.  Encouraged to go to a specific group or class to help me cope with my chronic 
condition (n=434) 
2.78 (1.0 – 5.0) 1.54 
11.  Asked questions, either directly or on a survey, about my health habits (n=436) 3.13 (1.0 – 5.0) 1.44 
12.  Sure that my doctor or nurse thought about my values, beliefs, and traditions when 
they recommended treatments to me (n=436) 
3.41 (1.0 – 5.0) 1.43 
13.  Helped to make a treatment plan that I could carry out in my daily life (n=434) 3.30 (1.0 – 5.0) 1.44 
14.  Helped to plan ahead so I could take care of my condition even in hard times 
(n=436) 
3.08 (1.0 – 5.0) 1.51 
15.  Asked how my chronic condition affects my life (n=436) 3.20 (1.0 – 5.0) 1.49 
16.  Contacted after a visit to see how things were going (n=439) 2.62 (1.0 – 5.0) 1.53 
17.  Encouraged to attend programs in the community that could help me (n=433) 2.24 (1.0 – 5.0) 1.44 
18.  Referred to a dietician, health educator, or counselor (n=438) 2.61 (1.0 – 5.0) 1.50 
19.  Told how my visits with other types of doctors, like an eye doctor or other specialist, 
helped my treatment (n=439) 
2.82 (1.0 – 5.0) 1.53 
20.  Asked how my visits with other doctors were going (n=438) 2.60 (1.0 – 5.0) 1.53 
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addressed to optimize delivery of PCC and increase ratings 
of care within this patient population. Nearly half of the 
sample was characterized by lower levels of patient 
activation. Moreover, our data demonstrate gaps that may 
exist in delivering follow-up care, enabling patients to set 
specific goals related to their health, and informing 
patients about the risks and benefits associated with 
available treatment options for GERD.   
 
The overarching mission of the PCC model includes 
delivering high-quality care that is responsive to individual 
needs, supporting patient engagement in clinical care, and 
improving communication between patients and the health 
care system.24, 40 Given the overlap between PCC and 
patient experience principles,26 PRO measures that address 
PCC concepts may represent an important component to 
assess patient experiences and capture the perspectives of 
patients with burdensome, prevalent, and costly diseases.41 
Despite their value in evaluating care across a range of 
chronic conditions,42-44 the application of the PROs used 
in this study has not been previously explored in the area 
of GERD and remains limited within the broader 
gastrointestinal (GI) literature. Randell and colleagues45 
previously used the PACIC to assess care perceptions 
among individuals with inflammatory bowel disease (IBD), 
finding that respondents achieved lowest scores in the 
follow-up and coordination of care subscale. This is 
corroborated by our study, as well as several prior studies 
describing PACIC scores beyond GI diseases,46-49 and 
suggests that continuity of care is an important goal for 
quality improvement in GERD care. In prior studies 
exploring patient activation among individuals with IBD 
and irritable bowel syndrome (IBS), respondents achieved 
similar PAM scores compared to our sample.50-51 Given 
the chronic nature of GERD symptoms and a need for 
these patients to remain actively engaged throughout the 
care continuum, the PAM may be especially useful to 
identify patients with GERD who require additional 
support to manage their own health in contrast to 
activated patients who may be well-suited for self-
management interventions alone.  
 
Although our results delineate several existing strengths 
and gaps in the patient experience for Veterans with 
GERD, recent recommendations highlight a need to 
optimize use of PROs and translate PRO data into 
improved clinical practice.52 Our findings present a 
number of clinical implications and actionable next steps 
unique to the care of patients with GERD on PPI therapy. 
These PRO data can inform how the health care system 
can better support patients with GERD, including better 
understanding and enhancing patient activation, risk 
communication, and follow-up care. One key finding that 
emerged as a potential deficit within GERD care was the 
perceived risk communication related to GERD 
treatments. Despite their benefits to many patients, there 
is accumulating evidence around a broad range of risks 
and side effects associated with PPI use.18 More recently, 
widespread press coverage linking PPI use to dementia 
and chronic kidney disease have led to growing fears and 
concerns among PPI users.25, 53-54 Our findings underscore 
these concerns, and suggest that providers may need to 
pay particular attention to patients’ concerns and better 
inform patients of the risks and benefits related to PPIs 
and other GERD therapies. No prior studies have 
addressed patient experiences or communication in 
GERD care; however, in a study of outpatient care 
experiences in a broader GI patient population, Larkins et 
al found that GI patients perceived the quality of patient-
provider interaction to be integral to an optimal patient 
experience.55 This may be especially important to consider 
among GERD patients.  Quality improvement efforts may 
benefit from further engaging patients to determine how 
patient-provider communication and care processes can be 
enhanced to address patient concerns and preferences.  
 
Several limitations should be acknowledged. Our survey 
response rate was lower than expected and may not 
represent the greater Veteran population with GERD. 
Moreover, Veterans represent a population that is 
generally older and less educated compared to the 
American population overall;56 thus, our results may not 
be applicable to the broader population with GERD who 
use PPIs. The cross-sectional study design allowed us to 
examine patient perceptions at a given point of time only. 
Finally, the self-reported nature of our survey data may 
have introduced additional limitations.  
 
We contribute to existing literature by (1) using PROs to 
describe how patients with GERD on PPI therapy 
perceive care, and (2) harnessing patient perspectives that 
can be used to optimize care experiences to better align 
with the unique needs and preferences within this 
population. Our approach may be used by researchers and 
clinicians to characterize patient experiences among 
individuals with other chronic diseases beyond GERD. In 
this study, Veterans with GERD perceived care to be well-
organized, supportive in enhancing shared decision-
making, and effective in improving their understanding of 
care. However, several gaps may exist in delivering GERD 
follow-up care, enhancing patient activation, and 
informing patients about the risks and benefits of existing 
treatments. Findings can inform further investigation and 
development of targeted interventions to enhance the 
experience of PCC for patients with GERD. Further 
studies are needed to understand patient- and system-level 
factors independently associated with higher scores in 
some PCC domains, including shared decision-making and 
delivery system design, and lower scores in other domains, 
including risk communication and follow-up care. Efforts 
are also needed to explore if PCC outcomes are associated 
with GERD symptom control, particularly in areas of 
follow-up support, care coordination and risk 
communication. This may impact appropriate use of 




Patient Experience Journal, Volume 5, Issue 3 – 2018 157 
diagnostic testing and long-term medication use for an 
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